ALSO NOTED: Wyeth halts late-stage study; feds probe Cell Therapeutics' promotional work; Aricept study draws FDA's attention;

> Wyeth has decided to halt a late-stage trial of an experimental therapy for breast cancer in post-menopausal women. The therapy combined Novartis' Femara with experimental temsirolimus oral tablets. Report

> The feds are probing Cell Therapeutics' promotional work for the leukemia drug Trisenox. According to a company filing, prosecutors are examining whether Cell Therapeutics promoted the drug for unapproved use. Drugs are often prescribed for unapproved uses, but companies are not allowed to promote them. Article

> The death of 11 patients in a recent Aricept study has drawn the attention of the FDA. Article

> Teva says it expects to regain marketing exclusivity for generic Pravachol back after an appeals court directed the FDA to reexamine the matter. Report

> The FDA has approved Schering's Yaz birth control pill. Report

> Barr says that the FDA will not need new data to approve Seasonique, a birth control pill. Report

> The FDA has approved Salix Pharmaceuticals' colon cleansing agent. Report

> NAEJA Pharmaceutical has inked a $10.2 million research deal with AstraZeneca Canada. Report

> Stem Cell Therapeutics reported positive Phase I data for its lead candidate for stroke. Report

> Meridian Biosciences has received FDA approval for a new test kit for stomach ulcers. Report

> ImClone Systems has agreed to pay $32 million to the IRS to resolve a tax audit. Report

And Finally... New research suggests that 'memory robbing' proteins may be an early sign of Alzheimer's. Article